AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
- Mechanism
- Curator reviewed
AT9283 is an inhibitor of mitosis (cell division) and is the second most progressed drug candidate in the Astex portfolio of novel molecularly targeted cancer drugs. All of Astex’s current products have been discovered internally using its proprietary drug discovery approach. AT9283 is a potent inhibitor of the Aurora A and B kinases and has been shown to arrest tumour growth in a range of tumour models. Aurora kinases play a key role in mitotic checkpoint control in cell division. Both Aurora A and B are over-expressed in many human tumours and are believed to be excellent targets for anti-cancer therapy.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), leukemia (myeloid), and solid tumors.Curator reviewed
- Formula / weight
- C19H23N7O2 · 381.44 g/mol (avg)
- Also known as
- 1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
- Code names
- AT 9283
Resolves to
LOLPPWBBNUVNQZ-UHFFFAOYSA-NSMILESOC(NC1=CNN=C1C1=NC2=C(N1)C=CC(CN1CCOCC1)=C2)=NC1CC1What you can answer from here — as of June 15, 2026
Which drugs share a target with AT9283, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account